TY - CHAP
T1 - Immunotherapy-Mediated Luminal Gastrointestinal Toxicities
AU - Thomas, Anusha S.
AU - Wang, Yinghong
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.
PY - 2021
Y1 - 2021
N2 - The advent of immune checkpoint blockade and its application in the management of advanced malignancies has revolutionized cancer therapies, outcomes, and survival. As beneficial as these class of drugs have been proven to be, their use is not devoid of complications, viz., immune-related adverse events (irAEs). The gastrointestinal (GI) tract is the second most frequently affected organ system, and toxicities may vary in severity from mild disease to aggressive life-threatening clinical presentations. Timely diagnosis that incorporates clinical, biochemical, imaging, endoscopic, and histologic evaluation is imperative for efficacious management of this disease process to ensure good outcomes. Management varies depending on severity and can comprise supportive care in milder disease patterns as well as vigorous immunosuppression in aggressive cases.
AB - The advent of immune checkpoint blockade and its application in the management of advanced malignancies has revolutionized cancer therapies, outcomes, and survival. As beneficial as these class of drugs have been proven to be, their use is not devoid of complications, viz., immune-related adverse events (irAEs). The gastrointestinal (GI) tract is the second most frequently affected organ system, and toxicities may vary in severity from mild disease to aggressive life-threatening clinical presentations. Timely diagnosis that incorporates clinical, biochemical, imaging, endoscopic, and histologic evaluation is imperative for efficacious management of this disease process to ensure good outcomes. Management varies depending on severity and can comprise supportive care in milder disease patterns as well as vigorous immunosuppression in aggressive cases.
KW - Colitis
KW - Diarrhea
KW - Enterocolitis
KW - Gastrointestinal adverse events
KW - Immune checkpoint inhibitors
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85122432163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122432163&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-79308-1_12
DO - 10.1007/978-3-030-79308-1_12
M3 - Chapter
C2 - 34972972
AN - SCOPUS:85122432163
T3 - Advances in Experimental Medicine and Biology
SP - 331
EP - 337
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -